Clinical trials: Neoplasm, Gastrointestinal
Pancreatic Cancer
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have…
- Trial name
- NCT03165188
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- NewLink Genetics Corporation
Colorectal Cancer, Advanced Adenocarcinoma
Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
This study was a prospective analysis conducted by Geneoscopy Inc. to evaluate the ColoSense test, which is a multi-target stool RNA test for colorectal cancer screening.
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma, Serrated Polyp
- Trial name
- CRC-PREVENT (NCT04739722)
- Testing
- ColoSense
- Where
- 2 sites in United States
- Volunteers
- 14,263 people, healthy volunteers welcome
- Sponsor
- Geneoscopy, Inc.
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Metastatic Hepatocellular Carcinoma, HCC
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
This single arm, open label, two stage study will be conducted in several medical centers around Taiwan. Stage one determine safety and tolerability in patients with HCC, and stage two assess anti-tumor activities of GT90001 in…
- Conditions
- Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
- Trial name
- NCT03893695
- Testing
- GT90001 and Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Colorectal Neoplasm, Iron Deficiency Anemia
Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
The main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard…
- Trial name
- NCT00199277
- Testing
- i.v. iron sucrose, Oral iron
- Where
- 5 sites in Spain
- Volunteers
- 150 people
- Sponsor
- J. Uriach and Company
Stomach Neoplasms
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
- Trial name
- NCT00553696
- Testing
- Cisplatin, S-1, Sunitinib
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
The primary objectives of the study are: Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies Recommend a dose for subsequent studies of IPI-504
- Trial name
- NCT00276302
- Testing
- IPI-504
- Where
- 5 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Pancreatic Cyst, Pancreatic Neoplasms
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
This study focuses on four different lesions: pancreatic cysts, lymph nodes near the gastrointestinal tract, pancreatic masses and GIST tumors.
- Conditions
- Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer
- Trial name
- US-nCLE (NCT01770405)
- Testing
- Endoscopic ultrasound fine needle aspiration
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mauna Kea Technologies
Colorectal Cancer
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in…
- Trial name
- NCT00234429
- Testing
- Gefitinib, raltitrexed
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Study of PTS100 in Primary HCC Patients
This study is being performed to evaluate the efficacy and safety of 30% PTS100 of total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma patients who are ineligible for operation or local…
- Trial name
- OASES (NCT03447951)
- Testing
- Para-Toluenesulfonamide
- Where
- 3 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Gongwin Biopharm Co., Ltd.
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase)…
- Conditions
- Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
- Trial name
- SPICE (NCT02636036)
- Testing
- enadenotucirev, nivolumab
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Akamis Bio
Hepatocellular Carcinoma
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
The purpose of this study is to compare the overall survival (OS) for Orantinib in combination with transcatheter arterial chemoembolization (TACE) versus placebo in combination with TACE in patients with unresectable…
- Trial name
- ORIENTAL (NCT01465464)
- Testing
- Orantinib (TSU-68)
- Where
- 6 sites in Japan, South Korea and 1 more
- Volunteers
- 888 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Colorectal Neoplasms
Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
This protocol describes procedures for the collection of blood samples for the intent of determining genetic contribution to the safety and efficacy of CPT/FU/LV.
- Trial name
- NCT00140036
- Testing
- Blood draw
- Where
- 34 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- Pfizer
Barrett's Esophagus
High Resolution Optical Imaging of Barrett's Esophagus Using Nvision Volumetric Laser Endomicroscopy (VLE)
The primary objective of this clinical trial is to evaluate the performance of the Nvision Volumetric Laser Endomicroscopy (VLE) system to visualize subsurface tissue in subjects undergoing esophagogastroduodenoscopy (EGD) and to…
- Trial name
- NCT01503411
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- NinePoint Medical
Hepatocellular Carcinoma (HCC)
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
- Trial name
- NCT03516071
- Testing
- Brivanib 800 mg, QD, Brivanib 400 mg, BID
- Where
- 15 sites in China
- Volunteers
- 90 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
BRAF V600E Mutation Positive, Metastatic Colorectal Cancer
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in patients with mCRC, and findings from clinical trials have largely remained inconclusive regarding the efficacy of first line treatments for…
- Trial name
- CAPSTAN CRC (NCT04317599)
- Testing
- Non interventional
- Where
- 34 sites in Austria, Belgium and 5 more
- Volunteers
- 274 people
- Sponsor
- Pierre Fabre Medicament
Hepatocellular Carcinoma
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted…
- Trial name
- NCT00073736
- Testing
- MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day
- Where
- 4 sites in United States, Hong Kong and 1 more
- Volunteers
- 28 people
- Sponsor
- Ligand Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.